Despite HDAC inhibitors being a novel class of potent anticancer drug, previous studies have revealed that exposure of cancer cells to HDAC inhibitors can lead to broad-spectrum anticancer MDR, resulting in cells that are resistant to numerous structurally and functionally unrelated drugs (27). This evidence concerns the gene HDAC9 and cancer.